These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8482565)

  • 1. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
    Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
    Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated mucin-type glycoprotein (CA54/61) defined by two monoclonal antibodies (MA54 and MA61) in ovarian cancers.
    Nozawa S; Yajima M; Kojima K; Iizuka R; Mochizuki H; Sugawara T; Iwamori M; Nagai Y
    Cancer Res; 1989 Jan; 49(2):493-8. PubMed ID: 2910468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and clinical evaluation of tumor-associated antigen CA54/61 identified by monoclonal antibodies MA54 and MA61 in epithelial ovarian cancer.
    Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
    Gynecol Oncol; 1992 Dec; 47(3):328-36. PubMed ID: 1473746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The usefulness and limitation of sugar antigen in ovarian cancers--with special reference to a new tumor marker, CA54/61].
    Nozawa S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1147-51. PubMed ID: 2499263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of a tumor marker (CA54/61) and its individual epitopes recognized by monoclonal antibodies, MA54 and MA61, in human tumor patients.
    Mochizuki H; Nagoya K; Yamauchi T; Takao Y; Masuko H; Sato H; Sasaki H; Itoh K; Tsukazaki K; Udagawa Y
    J Clin Lab Anal; 1992; 6(4):225-31. PubMed ID: 1383482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
    Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum sialyl Tn antigen as a prognostic marker in patients with epithelial ovarian cancer].
    Kobayashi H; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):14-20. PubMed ID: 1541859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
    Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
    Liu W
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
    Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
    Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.